Fertility warning
This medicine may affect fertility.
Leaflet LAPATINIB STADA 250mg film-coated tablets
Precautions:
Cytotoxic / special handling
Handle with special care.
Contraception required
Effective contraception is required during treatment.
Contraindicated during breastfeeding
Do not use this medicine while breastfeeding.
Contraindicated during pregnancy
Do not use this medicine during pregnancy.
Avoid grapefruit
Avoid grapefruit and grapefruit juice.
Hepatotoxicity
This medicine may affect the liver.
Major drug interactions
This medicine may have important interactions with other medicines.
Myelosuppression / agranulocytosis
This medicine may lower blood cell counts.
Additional monitoring
This medicine is subject to additional monitoring.
Requires periodic laboratory tests
Periodic laboratory tests may be required during treatment.
Severe skin reactions
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Cardiac risk / QT prolongation / arrhythmias
This medicine may increase the risk of heart rhythm disturbances.
Lapatinib is a medication used to treat advanced or metastatic breast cancer, particularly in cases where tumors overexpress the HER2 receptor. It is a tyrosine kinase inhibitor that blocks cellular signaling involved in cancer cell growth and survival.
The medication is taken orally, usually once daily, and is used in combination with other therapies such as capecitabine or letrozole. Treatment is carried out under the supervision of an oncologist.
Side effects may include diarrhea, nausea, skin rash, fatigue, or loss of appetite. In rare cases, severe adverse effects such as liver or cardiac toxicity may occur.
Patients should inform their doctor about any other medications they are taking and strictly follow the administration instructions. Pregnant or breastfeeding women should not use this medication.
The medication is taken orally, usually once daily, and is used in combination with other therapies such as capecitabine or letrozole. Treatment is carried out under the supervision of an oncologist.
Side effects may include diarrhea, nausea, skin rash, fatigue, or loss of appetite. In rare cases, severe adverse effects such as liver or cardiac toxicity may occur.
Patients should inform their doctor about any other medications they are taking and strictly follow the administration instructions. Pregnant or breastfeeding women should not use this medication.
General data about LAPATINIB STADA 250mg
- Substance:
- lapatinib
- Date of latest medicines list:
- 01-10-2022
- Product code:
- W69108001
- Concentration:
- 250mg
- Pharmaceutical form:
- film-coated tablets
- Quantity:
- 70
- Product type:
- Generic medicine
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.